Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

4 October 2017

Source Multiple Sclerosis News Today:

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions.  Read on.

Blog categories: 

Category

Archive